Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disorder resulting from motor neuron death. Approximately 10% of cases are familial (FALS), typically with a dominant inheritance mode. Despite numerous advances in recent years [1] [2] [3] [4] [5] [6] [7] [8] [9] , nearly 50% of FALS cases have unknown genetic aetiology. Here we show that mutations within the profilin 1 (PFN1) gene can cause FALS. PFN1 is crucial for the conversion of monomeric (G)-actin to filamentous (F)-actin. Exome sequencing of two large ALS families showed different mutations within the PFN1 gene. Further sequence analysis identified 4 mutations in 7 out of 274 FALS cases. Cells expressing PFN1 mutants contain ubiquitinated, insoluble aggregates that in many cases contain the ALS-associated protein TDP-43. PFN1 mutants also display decreased bound actin levels and can inhibit axon outgrowth. Furthermore, primary motor neurons expressing mutant PFN1 display smaller growth cones with a reduced F/G-actin ratio. These observations further document that cytoskeletal pathway alterations contribute to ALS pathogenesis.
To identify causative genes for familial ALS, we performed exome capture followed by deep sequencing on two large ALS families ( Fig. 1a , b) of Caucasian (family 1) and Sephardic Jewish (family 2) origin. Both display a dominant inheritance mode and are negative for known ALS-causing mutations, including the newly identified hexanucleotide repeat expansion in C9orf72 (refs 6, 8, 9; Supplementary Fig. 1 ). For each family, two affected members with maximum genetic distance were selected for exome sequencing. A high level of coverage (.3150) was achieved with an average of 1.1 3 10 10 and 2.3 3 10 10 base pairs sequenced for members of families 1 and 2, respectively ( Supplementary Tables 1 and 2 ). To identify candidate causative mutations, variants were identified and filtered, as in previous exome sequencing reports 5 , using several criteria: the variant is observed in both family members, alters the amino acid sequence, is not excluded by linkage analysis ( Supplementary Fig. 2) , and is absent from dbSNP132, the 1000 Genomes Project (May 2011 release) or the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP) Exome Variant Server (5,379 sequenced exomes; http://evs.gs.washington.edu/EVS/). Remaining variants were confirmed by Sanger sequencing and tested for Mendelian segregation in all affected family members. The resulting number of candidate causative mutations identified was two within family 1 and three within family 2 ( Supplementary Tables 3 and 4 ). Interestingly, the two families contain different mutations (C71G and M114T) within a single common gene: PFN1, located on chromosome 17p13.2. PFN1 is an 140-amino-acid protein and major growth regulator of filamentous (F)-actin through its binding of monomeric (G)-actin 10 . Asterisks indicate samples subjected to exome sequencing. To prevent identification of individual family members, the gender of each subject and information on the lower generation are withheld. Genotypes of available DNA samples for the indicated PFN1 mutation are shown ('w' denotes wild type, 'm' denotes mutant). The genotype of sample III:2 in family 2 (1) was inferred from the genotypes of spouse and progeny (not shown). d, The evolutionary conservation of PFN1 mutations is shown. For each, the mutated amino acid is coloured red.
On the basis of these data, we tested the hypothesis that PFN1 gene mutations cause familial ALS. Figure 1 shows sequence analysis of all available members of families 1 and 2. All four affected members of family 1 for which DNA was available possess the PFN1(C71G) variant. A single obligate carrier of the C71G variant (III:13) did not develop disease; however, death occurred before the average age of onset of this family (Supplementary Table 5 ). All unaffected family 1 members displayed the wild-type genotype (Fig. 1a ). Within family 2, all eight affected members for which DNA was available contained the M114T variant. On the basis of the genotypes of spouse and progeny (not shown), we confirmed that a ninth affected family member (III:2) also carries the mutation. Of 7 unaffected members, 5 do not contain the M114T variant. One unaffected mutation carrier is now in their mid-40s (III:15) and a second obligate carrier (II:4) was asymptomatic into their 70s ( Fig. 1b ). Our results suggest that these mutations have a high degree of penetrance. Affected-only linkage analysis of the PFN1 variants in family 1 and 2 yielded a logarithm of the odds (lod) scores of 1.80 and 2.71, respectively.
To determine whether PFN1 mutations cause familial ALS, the coding region was sequenced in a panel of 272 further FALS cases prescreened for common causative mutations. Five other familial ALS cases containing alterations in the PFN1 gene ( Supplementary  Figs 3 and 4 ) were identified. Interestingly, the C71G alteration originally identified in family 1 was discovered in two other families. For one of these families (family 3), DNA was available for three other affected family members. Sequencing of these samples showed that the mutation co-segregates with ALS ( Fig. 1c ). A single unaffected member of the family (IV:2) also contains the mutation; the current age of this family member is mid-40s. Affected-only linkage analysis of family 3 yielded a lod score of 1.50 and a combined lod score of 6.01 for families 1-3. A second M114T mutation was identified in an ALS family of Italian origin (family 4, Supplementary Fig. 3 ). DNA available for one sibling was shown by sequencing to contain this mutation. PFN1 variants were observed in two other FALS cases: a consecutive base-pair change (AA to GT) resulting in an E117G mutation, and a G-to-T transversion resulting in a G118V mutation ( Supplementary Figs 3 and 4 ). DNA was not available from other family members for these cases. Sequencing of the PFN1 coding region in 816 sporadic ALS (SALS) samples identified two samples containing the E117G mutation. No further non-synonymous changes were identified in the FALS and SALS samples (Supplementary Table 6 ). Haplotype analysis using surrounding single nucleotide polymorphisms (SNPs) suggests that the C71G mutation derives from a single ancestral mutation ( Supplementary Table 7 ).
To confirm further that the newly identified variants (E117G and G118V) represent causal mutations, not benign polymorphisms, each was interrogated in the 1000 Genomes Project database and the NHLBI ESP Exome Variant Server. The G118V mutation was not identified in either database. However, the E117G variant was observed in 2 samples out of 5,379 at the NHLBI ESP Exome Variant Server. We extended this analysis by genotyping all mutations in an independent set of 1,089 control samples. Three of the mutations (C71G, M114T and G118V) were not observed in the 1,089 control samples; however, the E117G variant was observed in a single control ( Supplementary  Table 8 ). By combining data from the 1000 Genome Project, the NHLBI ESP Exome Variant Server and independent genotyping, three of the ALS-linked variants were not present in 7,560 control samples (15,120 alleles), whereas the fourth (E117G) was found in 3 out of 1,090 ALS cases and in 3 out of 7,560 control samples (2.75 3 10 23 versus 3.97 3 10 24 ; P 5 0.030, two-tailed Fisher's exact test). Thus, it could be argued that the E117G variant is either non-pathogenic or, more likely, represents a less pathogenic mutation.
In total, we identified 4 mutations in 7 out of 274 FALS cases. In each case, the altered amino acid was evolutionarily conserved down to the level of zebrafish ( Fig. 1d ), supporting the possibility that these mutations are pathogenic. The age of onset for FALS cases with PFN1 mutations is 44.8 6 7.4 (Supplementary Table 5 ). All PFN1 mutant cases displayed limb onset; no bulbar onset was observed (n 5 22, Supplementary Table 5 ). Given that bulbar onset represents ,25% of ALS cases 11 , this result suggests a common clinical phenotype among patients with PFN1 mutations.
Ubiquitinated, insoluble aggregates are pathological hallmarks of several neurodegenerative diseases including ALS, Parkinson's disease and Alzheimer's disease. To investigate whether the observed PFN1 mutants form insoluble aggregates, western blot analysis of NP-40soluble and insoluble fractions was performed on Neuro-2A (N2A) cells transfected with wild-type or one of the four PFN1 mutants. PFN1 protein was present predominantly in the soluble fraction of cells transfected with the wild-type construct as compared with the insoluble fraction ( Fig. 2a ). Conversely, a considerable proportion of the C71G, M114T and G118V mutant proteins were detected in the insoluble fraction. Furthermore, several higher molecular mass species were 
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observed, indicative of SDS-resistant PFN1 oligomers. However, the E117G mutant displayed a pattern more similar to wild-type PFN1 with most of the expressed protein in the soluble fraction. Differential expression of PFN1 constructs was ruled out by western blot analysis of whole cell lysates ( Supplementary Fig. 5 ). Analysis of lymphoblast cell lines derived from affected and unaffected members of family 1 did not display any differences in PFN1 protein solubility ( Supplementary  Fig. 6 ). Autopsy material was not available for any affected individual.
We extended these observations by staining the PFN1 protein in transfected cells. Wild-type PFN1 exhibited a diffuse cytoplasmic expression pattern in transfected N2A cells (Fig. 2c) , as previously reported 12 . By contrast, ALS-linked PFN1 mutants often assembled into cytoplasmic aggregates. Image analysis determined that 15-61% of mutant-expressing cells contain cytoplasmic aggregates, including the E117G mutant, which showed minimal insoluble PFN1 protein by western blot analysis. No aggregates were observed for cells expressing wild-type PFN1 (Fig. 2e ). Co-staining revealed that these aggregates were also ubiquitinated. Primary motor neurons (PMNs) expressing the C71G, M114T and G118V mutants similarly demonstrated ubiquitinated aggregates, albeit at a lower percentage (Fig. 2d) ; aggregates were not observed in cells expressing the E117G mutant or wild-type PFN1. Immunoprecipitation of the PFN1 protein followed by western blot analysis confirmed that the insoluble mutant PFN1 protein is polyubiquitinated ( Supplementary Fig. 7) .
To determine whether ubiquitin-proteosome system impairment causes accumulation of mutant PFN1 aggregates, transfected N2A cells were exposed to the proteasome inhibitor MG132. ALS-linked PFN1 mutants, including E117G, showed increased insoluble protein levels and increased levels of higher molecular mass species by western blot analysis. Minimal insoluble protein was observed for the wild-type PFN1 protein (Fig. 2b ). PFN1 staining in N2A cells and PMNs confirmed these results. Cells expressing C71G, M114T and G118V mutant PFN1 had numerous, large aggregates after MG132 treatment. E117G mutants showed a moderate aggregate level, and the wild-type protein displayed minimal levels ( Supplementary Figs 8 and 9) .
Given the propensity of mutant PFN1 to form aggregates, we investigated whether other ALS-related proteins may be present within these aggregates. Thus, we transfected PMNs with mutant PFN1 and tested for alterations in the cellular localization of the ALS-related proteins FUS and TDP-43. Furthermore, we also tested for alterations in the spinal muscular atrophy-related protein SMN owing to its ability to bind PFN1 (ref. 13) . No co-aggregation of either FUS or SMN with mutant PFN1 was observed ( Supplementary Figs 10  and 11 ). However, ,30-40% of cells contained cytoplasmic PFN1 aggregates co-stained with TDP-43 ( Fig. 2f) . These results suggest that mutant PFN1 may contribute to ALS pathogenesis by inducing aggregation of TDP-43. On the basis of these observations, we investigated whether aggregates of TDP-43 contain PFN1 by staining spinal cord tissues from 18 SALS cases displaying TDP-43 pathology and 6 non-ALS controls without TDP-43 pathology ( Supplementary Fig. 12 ). Abnormal PFN1 pathology was not discovered in SALS cases, suggesting that TDP-43 aggregation does not induce PFN1 aggregation. Expression of the carboxy-terminal fragment of TDP-43, which produces insoluble aggregates, in PMNs also failed to co-aggregate wildtype PFN1, thus supporting this observation ( Supplementary Fig. 13 ).
Evaluation of the PFN1-actin complex crystal structure showed that all ALS-linked mutations lie in close proximity to actin-binding residues of PFN1 (ref. 14; Fig. 3a ). Therefore, we investigated whether the ALS-linked mutations display a decreased level of bound actin. Towards this end, we performed immunoprecipitation and western blot analysis of cells transfected with wild-type and mutant PFN1. As a control, we also transfected cells with a construct expressing a synthetic PFN1(H120E) mutant protein. This alteration is located at a crucial residue previously shown to abolish PFN1 binding to actin 12 . We observed that C71G, M114T, G118V and H120E mutants had reduced levels of bound actin relative to wild-type PFN1 (Fig. 3b) .
The E117G mutant did not show a reduction of bound actin relative to wild-type PFN1.
Previous reports have shown that PFN1 protein alterations inhibit neurite outgrowth 12, 15 . We investigated whether ALS-linked PFN1 mutants inhibit neurite outgrowth by measuring axonal length in PMNs transfected with wild-type or mutant PFN1. As a positive control, we also transfected PMNs with the H120E-expressing construct. In addition to lacking actin-binding ability, the H120E protein inhibits neurite outgrowth 12 . As expected, the H120E-expressing cells displayed a pronounced decrease in axon length relative to the wild-type construct (Fig. 3d) . Three ALS-linked PFN1 mutations (C71G, M114T and G118V) also showed a significant decrease in axon outgrowth (Fig. 3c, d) . In particular, the G118V-associated reduction is similar to that observed with the H120E construct. Axon outgrowth inhibition was observed with the E117G mutant but did not reach statistical significance. These results suggest that mutations in PFN1 may contribute to ALS pathogenicity in part by inhibiting axon dynamics.
The regulation of actin dynamics in the growth cone is necessary for axon outgrowth. Defects in PFN1 are associated with growth cone ; green: actin-binding PFN1 residues; red: ALS-linked mutated PFN1 residues. b, Transfected HEK293 cells were immunoprecipitated with a V5 antibody and then immunoblotted with antibodies for either V5-PFN1 or actin. c, PMNs transfected with wild-type or mutant V5-PFN1 and a green fluorescent protein (GFP)-expressing construct were stained to detect V5-PFN1. The axon tip, indicated by arrows, is enlarged in the inset, right panel. Scale bars, 100 mm. d, Cumulative distribution of axon lengths relative to the mean of wild-type PFN1-transfected cells was plotted. P values are given in the legend (n 5 104-161 cells from four independent experiments).
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arrest and reduced axon outgrowth in embryonic motor neurons of Drosophila 15 . To determine whether ALS-linked PFN1 mutants have a similar phenotype, PMNs transfected with wild-type and two mutant PFN1 constructs (C71G and G118V) were stained to detect F-and G-actin localization patterns in the highly dynamic and actin-rich growth cone. These mutants were selected owing to their greater influence on axon outgrowth. PFN1 mutant expression in PMNs led to a significantly reduced growth cone size (,43-52%) relative to wildtype PFN1 (Fig. 4b) . Also, mutant PFN1 expression significantly altered growth cone morphology. In wild-type PFN1-expressing cells, growth cones had elaborate structures with several F-actin rich filopodia (Fig. 4a) , whereas virtually no filopodia were visible in the mutant PFN1 growth cones. Similar results were observed for the synthetic H120E mutant defective in actin binding. The growth cones in mutant-expressing PMNs also had a lower ratio of F/G-actin relative to wild-type-expressing PMNs (Fig. 4c) . In particular, the C71G mutant-expressing PMNs displayed an F/G-actin ratio 24.4% of the wild-type expressing PMNs. These results suggest that mutant PFN1 can inhibit the conversion of G-actin to F-actin within the growth cone region, thus affecting its morphology. PFN1 expression is ubiquitous in non-muscle cells, whereas PFN2 is expressed in brain and neuronal tissues 16 , and PFN3 in the testis 17 . To determine whether mutations in PFN2 or PFN3 may also contribute to FALS, we sequenced the entire coding sequence of both genes in 274 FALS cases. In contrast to PFN1, no non-synonymous alterations were observed in these FALS cases ( Supplementary Table 6 ), which suggests that PFN2 and PFN3 mutations are not an important cause of FALS.
Here, we have applied exome sequencing to two large families displaying ALS. Through this approach, we were able to restrict the number of causal candidates in each family to two and three genes. Fortuitously, both families had mutations in the same gene, PFN1. Although we cannot rule out the possibility that mutations in other candidate genes may be causative, several lines of evidence demonstrate PFN1 as the causative gene. First, we identified a further five families with mutations in the PFN1 gene, including a third large family in which we confirmed segregation of the mutations. Second, mutant PFN1 displayed aggregation propensities analogous to those of other proteins implicated in neurodegenerative diseases such as ALS. Third, the mutants displayed several functional differences compared with the wild-type protein, including a lower bound actin level, an axonal outgrowth inhibition, and growth cone size reduction. Taken together, these results strongly support the view that mutations in the PFN1 gene cause familial ALS.
PFN1 is an intensely studied protein owing in part to its regulation of actin polymerization. PFN1 promotes nucleotide exchange on actin, converting monomeric ADP-actin to ATP-actin 10 . PFN1-ATP-actin complexes can bind to the fast-growing end of actin filaments. Dissociation of the complex allows the ATP-actin monomer to be added to the growing actin filament 18 . Here we show that mutant PFN1 may contribute to ALS pathogenesis by altering actin dynamics and inhibiting axon outgrowth. Similarly, expression of either mutant SOD1 (ref. 19) or mutant TDP-43 (ref. 20) inhibits neurite outgrowth, and primary neurons from FUS-deficient mice have reduced spine numbers and abnormal morphology 21 . These observations suggest a common pathogenic feature among diverse ALS genes. However, there is also the possibility that alterations to other PFN1 functions may contribute to the pathogenesis. PFN1 is also a complex regulator of cellular processes through its interactions with several proteins. Indeed, it has been shown to interact directly with more than 50 proteins (reviewed in ref. 22 ). Of interest, PFN1 directly interacts with three proteins that, when mutated, cause neurodegenerative disease-VCP (ALS-frontotemporal dementia, inclusion body myositis and Paget's disease) 16 ; SMN (spinal muscular atrophy) 13 ; and HTT (Huntington's disease) 23 .
There is increasing evidence that cytoskeletal defects have a major role in motor neuron diseases. Rarely, mutations in genes encoding neurofilament heavy polypeptide (NEFH) 24 , peripherin (PRPH) 25 and dynactin (DCTN1) 26 are associated with ALS. Spastin 27 Here we report that mutations in the PFN1 gene account for 1-2% of FALS. Our observations emphasize that disruption of cytoskeletal pathways contribute importantly to ALS pathogenesis.
METHODS SUMMARY
Exome sequencing was accomplished using an exome array (SeqCap EZ Exome Library, Nimblegen) adapted for sequencing on the Illumina DNA sequencing platform. Alignment of sequence to the human genome and variant detection was accomplished using the applications SOAPaligner and SOAPsnp. Expression constructs for wild-type and mutant PFN1 were transfected into N2A cells using Lipofectamine 2000 (Invitrogen). Inhibition of proteasome activity in N2A cells was performed by incubation with 10 mM MG132 (Sigma-Aldrich) after transfection for 16h before collection. Insolubility of PFN1 mutants was assessed by sequential NP-40/urea protein extraction followed by western blot analysis. Transfected HEK293 cells were lysed at 24 h with RIPA buffer and immunoprecitated with an anti-V5 antibody to investigate the interactions of PFN1 and actin. Primary motor neurons were isolated and cultured from embryonic day (E)13.5 mouse embryos and transfected by magnetofection. Axon length measurements were determined from low magnification images (310). The length of the longest axon branch was measured using ImageJ plug-in NeuronJ. F-actin and G-actin were labelled with fluorescent-conjugated Phalloidin (Invitrogen) and DNase I 
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(Invitrogen), respectively. Deconvolution of images was performed using Autoquant (MediaCybernetics). The growth cone area and the fluorescence intensity for F-actin and G-actin staining were measured using ImageJ software.
Full Methods and any associated references are available in the online version of the paper.
